- Earliest timepoint in an open-label extension with this magnitude of risk reduction at 44.7% in ACM (p<0.0001) and 49.3% in CVM (p<0.0001) -Acoramidis mitigated the rise in NT-proBNP through Month ...

- Earliest timepoint in an open-label extension with this magnitude of risk reduction at 44.7% in ACM (p -Acoramidis mitigated the rise in NT-proBNP through Month 54 to an extent not seen in the era ...

Alnylam has big ambitions for Amvuttra. But despite an explosive transthyretin amyloid cardiomyopathy (ATTR-CM) launch in 2025, three questions remain: potential upcoming competition from AstraZeneca ...

Good morning, everyone, and thank you for joining us today. I'm Tolga Tanguler, Chief Commercial Officer at Alnylam, and I'm thrilled to be hosting today's webinar to update you on our leadership ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

His voice is easily among the most recognizable in the world. Award-winning actor Morgan Freeman has a presence that can command a room without stepping into it. On and off screen, his steady baritone ...

Kevin M. Alexander, MD, eagerly awaits the presentation of new amyloid dataat the 2026 ACC meeting in New Orleans and is especially interested in the subgroup analyses from the ATTRibute-CM and HELIOS ...

Long-term ATTR-CM trial data show durable benefits with early tafamidis or acoramidis, fewer deaths/hospitalizations, and manageable safety. This episode, titled ‘Key Efficacy and Safety ...

Learn how TTR stabilizers and gene silencers curb amyloid buildup in ATTR-CM, with trial evidence for fewer hospitalizations and better survival. In ‘Evaluating Transthyretin Stabilizers and Silencers ...

Coramitug is a potential first-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy 1-3 Prothena has now earned $150 million to date of the $1.2 billion total ...

Life expectancy for people with ATTR amyloidosis varies, generally ranging from 3 to 15 years after symptoms appear, and depends on the specific type of the condition and any other health issues a ...